





The successful use of Denosumab to treat osteoporosis in a patient with severe Anorexia Nervosa

Andrew Jamieson¹,², Anthony J Pelosi³ and Georgina Weatherdon¹

¹St John's Hospital, Livingston, West Lothian EH54 6PP ²School of Medicine, University of Glasgow ³Tertiary Eating Disorders Specialist Service, NHS Lanarkshire

For further information please contact: and rew.x.jamieson@nhslothian.scot.nhs.uk

Background

Women with persistent Anorexia Nervosa are highly likely to develop osteoporosis and fractures (1).

The presence of low bone mineral density in a young woman with low body weight raises a challenging circumstance that can often provoke great anxiety for clinicians involved in the care of these patients. The best single treatment for low bone density for these patients is weight gain and it's maintenance at a normal body mass index but this can prove problematic in practice.





Case Description

A 29 year old female with a 17 year history of severe enduring anorexia nervosa attended our unit. Osteoporosis was diagnosed aged 24 and she had developed a left calcaneal fracture after minimal trauma 3 weeks prior to presentation (Figure 1). She had been amenorrhoeic continuously for 14 years. Her bone mineral density at this time confirmed the presence of osteoporosis at the lumbar spine and total hip (T-score -3.3 and -2.9 respectively) and her body mass index was low at 15.1 kg/m2. She declined therapy previously with oestrogen and bisphosphonate therapy and was not keen to undertake daily injections of teriparatide.


A decision was made to commence therapy with Denosumab 60mg by subcutaneous injection every six months with monitoring of serum calcium and co-administration of calcium and vitamin D. A further measurement of bone mineral density was made 2 months after completing three years of therapy with Denosumab. During the period of treatment the patient did not experience any adverse effects related to the treatment. There was no evidence of hypocalcaemia nor were there further fractures. The patient's BMI remained at 15.2 + 0.3.

Bone mineral density increased substantially at the lumbar spine (14.8% increase from pre-treatment) and at the left total hip site (1.4% increase from pre-treatment). The measurement at the left femoral neck showed a reduction of -5.7% from its pre-treatment value (Figure 2).


Discussion

Figure 1

Plain Radiography of right calcaneum showing undisplaced fracture in June 2012. The patient experienced pain following repeated walking.



Scan Date: 05 March 2015 ID: A0305151X Scan Type: a Lumbar Spine 05 March 2015 16:09 Version 13.5.3 Analysis: Operator: CS Model: Discovery A (S/N 81499) Comment:



score vs. White Female. Source:BMDCS/Hologic White Female. Z-score vs. White ale. Source BMDCS/Hologic White Female

Scan Date	Age	BMD (g/cm ²)	T -	vs Baseline BMD	Change vs Previous	
05.03.2015	32	0.789	-2.3	4.0%*	14.8%*	
11.06.2012	29	0.687	-3.3	-9.4%*	-8.3%*	
09.03.2011	28	0.750	-2.7	-1.1%	-1,1%	
20.11.2006	24	0.758	-2.6			
10000	THE REAL	F 2045-5-2-22		05 March 2015	ID: A0305151V	
1000				a Left Hip		
			Analysis:			
		Onemptore	Hip CS			
		Operator: Model:	Model: Discovery A (S/N 81499)			
		Comment:	Discovery A (SAV 8	(4)))		
100 412	min		c.c.m.em.		tail .	
100 100	1 100			**		
		1		CP CONTRACTOR CONTRACTOR	and the part of the	
Contraction of the				2	and the second se	

		S SALES			• • •	
C SHELL				** ** ********************************	- A - A	
		E 1998			e. 000 000	
		1 1997 1 1 1 1		ite Female. Source:BMDCS/ BMDCS/NHANES White P	NHANES White Female. Z-score v cenale.	
98 x 100 NECK: 49 x 15			TRAN	(* VIND Fracture Risk Assessment T	001	
DAP: 3.1 cGy*			W LOOK OF			
			10-year	Fracture Risk ¹		
				teoporotic Fracture	14%	
			Hip Fract	ure Lisk Factors:	8.3%	
			Reported P	USA FACTORS.		
			UK, T-score()	WHO]=-2.7, BMI=18.7, prev	ious fracture	

FRAX® Version 3.08. Fracture probability calculated for an untreated patient. Fracture probability may be lower if the patient has rece

Denosumab is a human monoclonal antibody that binds with high specificity to the receptor activator of nuclear factor-кВ ligand (RANKL) and results in decreased bone resorption, decreased bone turnover and reduces vertebral and nonvertebral fractures in postmenopausal women and can be safely administered for at least six years (4,5). The magnitude of the change in bone mineral density seen in post menopausal women treated with Denosumab is similar to that observed in this case despite the patient's ongoing low weight and suggests that this agent may be a useful therapy for treating osteoporosis in patients with anorexia nervosa and merits further investigation in the appropriate trial setting.

Following three years of successful event free treatment, the patient has opted to undertake a further and final three years of Denosumab therapy with ongoing monitoring for adverse effects.

Sean Date	Age	BMD (g/cm ²)	T - score	BMD Change	
				vs Baseline	vs Previous
05.03.2015	32	0.610	-2.7	-2.9%	1.4%
11.06.2012	29	0.601	-2.8	-4.2%	-3.9%
09.03.2011	28	0.626	-2.6	-0.3%	-0.3%
20.11.2006	24	0.628	-2.6		

Figure 2

DXA results showing response to treatment with Denosumab at Lumbar spine and total hip.

References

1) Rigotti, N. A., Neer, R. M., Skates, S. J., Herzog, D. B., & Nussbaum, S. R. (1991). The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA, 265(9), 1133-8.

2) Foo, J.-P., Hamnvik, O.-P. R., & Mantzoros, C. S. (2012). Optimizing bone health in anorexia nervosa and hypothalamic amenorrhea: new trials and tribulations. Metabolism: Clinical and Experimental, 61(7), 899–905.

3) Halmi, K. a, Agras, W. S., Crow, S., Mitchell, J., Wilson, G. T., Bryson, S. W., & Kraemer, H. C. (2005). Predictors of treatment acceptance and completion in anorexia nervosa: implications for future study designs. Archives of General Psychiatry, 62(7), 776-781.

4) Cummings, S. R., San Martin, J., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R, Christiansen, C. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England Journal of Medicine, 361(8), 756–765.

5) Bone, H.G., Chapurlat, R., Brandi, M.-L., Brown, J.P., Czerwinski, E., Krieg, M.-A., Papapoulos, S. (2013). The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. The Journal of Clinical Endocrinology and Metabolism, 98(11), 4483–92.